Findings Clarify Picture for HER2-Positive Breast Cancer

Lynne Lederman, PhD
Published: Tuesday, May 01, 2018
Adam M. Brufsky, MD, PhD

Adam M. Brufsky, MD, PhD
Major changes for patients with HER2- positive breast cancer are not on the horizon, but there are a number of new study findings that have amplified knowledge about how best to care for this population.

Dual-Targeted Neoadjuvant Therapy: Pertuzumab Plus Trastuzumab With Chemotherapy

Adam M. Brufsky, MD, PhD, session moderator, began the discussion by observing that interesting abstracts at SABCS covered both early and late disease. Neoadjuvant therapy in HER2-positive breast cancer has been a tremendous success, he said, noting research on determining the optimal chemotherapy backbone for using neoadjuvant trastuzumab (Herceptin) plus pertuzumab (Perjeta).
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication